NCT07647484Not yet recruiting
Peripheral Blood CyTOF and Viral Imprinting in Postoperative Multiple Pulmonary Nodules
A Multicenter Prospective Cohort Study of Peripheral Blood CyTOF Immune Phenotyping and Viral Imprinting in Patients With Postoperative Multiple Pulmonary Nodules
Source: ClinicalTrials.gov · Last updated 15 Jun 2026
Brief summary (registry, in English)
This multicenter prospective cohort study will enroll adults who have undergone resection of a primary pulmonary nodule and have residual multiple pulmonary nodules or require routine postoperative pulmonary nodule follow-up. During clinically indicated follow-up visits, a small amount of peripheral venous blood will be collected at the same time as routine blood draws for research CyTOF immune phenotyping and viral imprinting-related serology. The study will not assign participants to treatment, change follow-up schedules, imaging, medication, surgery, or other clinical care. Research laboratory results will not be returned to participants or entered into medical records. The study will describe longitudinal peripheral immune-cell profiles and explore associations among T/B/NK cell phenotypes, T-cell differentiation and senescence/exhaustion markers, viral imprinting markers, and postoperative residual or new pulmonary nodule evolution.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 2 Jun 2026
- Start date
- 1 Jul 2026
- Primary completion date
- 31 Dec 2028
- Lead sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- NCT number
- NCT07647484
What you commit to
- Study type: Observational
- Planned participants: 200
- From 1 Jul 2026 to the primary completion date, 31 Dec 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current strong immunosuppressive therapy that may substantially affect peripheral immune status and cannot be adequately recorded or adjusted for in analysis.
Other illness
- Investigator judges that the participant is unsuitable for additional small-volume blood collection, such as severe anemia, obvious coagulation abnormality, recent severe bleeding, or high risk of severe vasovagal reaction.
- Acute severe infection, acute major organ dysfunction, or other condition that may substantially affect peripheral immune status and makes study participation unsuitable.
- Any other condition that, in the investigator's judgment, makes participation inappropriate.
Other
- Unable to complete informed consent or explicitly refuses use of research blood samples and related data for this study.
Who the study is looking for
- Age 18 years or older, any sex. Primary pulmonary nodule has been surgically resected, with residual multiple pulmonary nodules or a need for pulmonary nodule-related routine postoperative follow-up.
- Planned routine postoperative follow-up at a participating center and able to provide a research blood sample together with routine blood draw when clinically available.
- Able to understand the study and willing to provide written informed consent before research blood sample collection.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.